Advertisement
MO BIO
MO BIO

Setback for Malaria Vaccine

The malaria vaccine under development by GSK and the PATH initiative only protects about one in three babies, though some researchers say those odds are better than nothing.

By | November 9, 2012

A boy waits with his mother for malaria test resultsFlickr, DVIDSHUBResults from a recent clinical trial testing the RTS,S malaria vaccine show that only a third of infants given the injection at 9 to 12 weeks of age were protected from the disease.  Although the study authors acknowledge the disappointing results, published last week (November 9) in the New England Journal of Medicine, they say that even a 30 percent reduction in the roughly 216 million cases of malaria could have a significant impact.

"The efficacy came back lower than we had hoped, but developing a vaccine against a parasite is a very hard thing to do," Bill Gates said in a statement.

The vaccine, developed by GlaxoSmithKline in collaboration with the PATH Malaria Vaccine Initiative, had shown better success rates in earlier studies on a smaller cohort of children in the same age group—65 percent—as well as in older children  vaccinated at between 5 and 17 months—55 percent. These success rates meet the  World Health Organization’s benchmark for malaria vaccines, which was put at 50 percent protection lasting longer than a year, but implementing a vaccine program at those ages could raise logistical issues. Vaccinating children at this later date is more difficult from a public health perspective because it couldn’t be combined with other childhood vaccinations, reported Reuters.  

The authors contend that the results only represent a portion of the Phase III results, with the data reported from only two of the 11 trial sites. Full results aren’t expected until 2014.   "To jump to conclusions is a disservice to the public," David Kaslow, director of the PATH Malaria Vaccine Initiative, told Nature. "We've been at this for 30 years, and we're certainly not going to give up now," GSK Chief Executive Andrew Witty told reporters on a conference call.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
R&D Systems
R&D Systems
Advertisement
The Scientist
The Scientist